Denmark meets US in biotech collaboration

Related tags Bacteria

Danish biotech company Fluxome Sciences , based at the Technical
University of Denmark, has entered a cooperation agreement with the
US biotech company Bio-Technical Resources concerning development
of optimised fermentation processes, reports the Danish website
Biotechdenmark.dk and Invest in Demark.

Danish biotech company Fluxome Sciences , based at the Technical University of Denmark, has entered a cooperation agreement with the US biotech company Bio-Technical Resources concerning development of optimised fermentation processes, reports the Danish website Biotechdenmark.dk and Invest in Demark​.

According to the report, the two companies have initially made a shared marketing agreement, but the plan is to jointly explore research and development projects with other biotech companies.

MD of Fluxome Sciences Jens Nielsen says that one of the promising areas is optimising the production of antibiotics. According to Nielsen, Fluxome is particularly good at understanding biochemical interactions within cells, the transformation of sugars into antibiotics and using genetic engineering to optimise processes.

Bio-Technical Resources has been present on the US market for more than 25 years and Jens Nielsen sees the new agreement as an opportunity to enter future contracts.

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars